Inhibikase Therapeutics Net Worth
Inhibikase Therapeutics Net Worth Breakdown | IKT |
Inhibikase Therapeutics Net Worth Analysis
Inhibikase Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Inhibikase Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Inhibikase Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Inhibikase Therapeutics' net worth analysis. One common approach is to calculate Inhibikase Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Inhibikase Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Inhibikase Therapeutics' net worth. This approach calculates the present value of Inhibikase Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Inhibikase Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Inhibikase Therapeutics' net worth. This involves comparing Inhibikase Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Inhibikase Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Inhibikase Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Inhibikase Therapeutics' net worth research are outlined below:
| Inhibikase Therapeutics generated a negative expected return over the last 90 days | |
| Inhibikase Therapeutics has high historical volatility and very poor performance | |
| Inhibikase Therapeutics may become a speculative penny stock | |
| Inhibikase Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (11.98 M). | |
| Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Latest headline from news.google.com: Inhibikase Therapeutics Stock Price Down 2.5 percent - Should You Sell - MarketBeat |
Inhibikase Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Inhibikase Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inhibikase Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Inhibikase Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibikase Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibikase Therapeutics backward and forwards among themselves. Inhibikase Therapeutics' institutional investor refers to the entity that pools money to purchase Inhibikase Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Mather Group, Inc. | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Redmond Asset Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 626.5 K | Blair William & Co | 2024-09-30 | 126.1 K | Geode Capital Management, Llc | 2024-09-30 | 50.1 K | Renaissance Technologies Corp | 2024-09-30 | 19.9 K | Vanguard Group Inc | 2024-09-30 | 16.7 K | State Street Corp | 2024-09-30 | 10.1 K |
Follow Inhibikase Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 133.18 M.Market Cap |
|
Project Inhibikase Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.18) | (1.24) | |
| Return On Capital Employed | (2.09) | (1.98) | |
| Return On Assets | (1.18) | (1.24) | |
| Return On Equity | (1.99) | (1.89) |
When accessing Inhibikase Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Inhibikase Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Inhibikase Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Inhibikase Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inhibikase Therapeutics. Check Inhibikase Therapeutics' Beneish M Score to see the likelihood of Inhibikase Therapeutics' management manipulating its earnings.
Evaluate Inhibikase Therapeutics' management efficiency
Inhibikase Therapeutics has Return on Asset of (0.7621) % which means that on every $100 spent on assets, it lost $0.7621. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4969) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2025. Return On Capital Employed is likely to gain to -1.98 in 2025. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.85 | 2.05 | |
| Tangible Book Value Per Share | 1.85 | 2.05 | |
| Enterprise Value Over EBITDA | 0.08 | 0.08 | |
| Price Book Value Ratio | 0.56 | 0.58 | |
| Enterprise Value Multiple | 0.08 | 0.08 | |
| Price Fair Value | 0.56 | 0.58 | |
| Enterprise Value | -2 M | -1.9 M |
Understanding the management dynamics of Inhibikase Therapeutics allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Enterprise Value Revenue 2.748 | Revenue | Quarterly Revenue Growth (1.00) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibikase Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibikase Therapeutics time-series forecasting models is one of many Inhibikase Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inhibikase Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Inhibikase Therapeutics Earnings per Share Projection vs Actual
Inhibikase Therapeutics Corporate Management
| Roger Rush | Head Research | Profile | |
| BSc FRCPC | Interim Advisor | Profile | |
| Garth LeesRolfe | Chief Officer | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Surendra Singh | Manufacturing Chemistry | Profile | |
| Dan Williams | Controller | Profile |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.